Results 21 to 30 of about 50 (49)
Dolutegravir Resistance and Failure in a Kenyan Patient [PDF]
The Journal of Infectious Diseases, 2018 Loice Achieng, David J. Riedel
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Dolutegravir–rilpivirine coformulation
Current Opinion in HIV and AIDS, 2018With prolonged life expectancy in HIV-positive patients on combination antiretroviral therapy, the quest for reducing lifelong drug exposure and minimizing or avoiding the toxicities of combination antiretroviral therapy while maintaining viral suppression has emerged when coformulations of antiretroviral agents with improved convenience, and better ...
Hsin-Yun Sun +2 more
openaire +2 more sources
Dolutegravir is not removed during hemodialysis
AIDS, 2016Item does not contain ...
Bollen, P.D. +3 more
openaire +5 more sources
Dolutegravir for the treatment of HIV
Expert Opinion on Investigational Drugs, 2012Development of new antiretroviral drugs which are highly potent, tolerable over the long term and with a high genetic barrier to resistance is essential for the treatment of a chronic viral disease that requires life-long therapy with near-perfect medication adherence.
Christine Katlama, Robert L. Murphy
openaire +3 more sources
Safety and efficacy of dolutegravir in hemodialysis
International Journal of STD & AIDS, 2019With the increasing incidence of chronic kidney disease in patients with human immunodeficiency virus (HIV), the number of HIV-infected patients requiring hemodialysis has also increased. Dolutegravir is an integrase inhibitor that is a common component of HIV treatment regimens.
Kayla N Kreft +2 more
openaire +3 more sources
Dolutegravir: First Global Approval
Drugs, 2013Dolutegravir, an orally administered HIV-1 integrase strand transfer inhibitor (INSTI), is under development by ViiV Healthcare. Like other drugs belonging in the INSTI class of antiretroviral agents, dolutegravir binds to the integrase site of HIV-1 and blocks the strand transfer integration step, thereby preventing the replication of HIV-1 ...
Caroline M. Perry, Anita D. Ballantyne
openaire +3 more sources
Dolutegravir as a trigger for DRESS syndrome?
International Journal of STD & AIDS, 2018Dolutegravir is an increasingly-used second-generation human immunodeficiency virus integrase strand transfer inhibitor. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome has been described in several patients treated with raltegravir but to our knowledge, there is no previous report of DRESS syndrome associated with dolutegravir.
Martin, Charlotte +2 more
openaire +3 more sources
Abacavir + dolutegravir + lamivudine for the treatment of HIV
Expert Opinion on Pharmacotherapy, 2016Since the last revision of both European and American guidelines (EACS and DHHS), new data from clinical trials and cohort studies, as well as experience in clinical practice, have prompted significant changes to the list of recommended/preferred options for the treatment of HIV infected patients, highlighted the role of INSTI-based regimens ...
Laura Comi, Franco Maggiolo
openaire +3 more sources
Dolutegravir: A new Option for Hiv Treatment
Future Virology, 2014ABSTRACT: The need for new strategies for treating HIV-1 infection has led to the development of a number of new drugs. The aim of this article is to review the latest results of clinical trials of dolutegravir, an integrase inhibitor whose efficacy, tolerability and safety have been confirmed in treatment-naive and treatment-experienced patients. The
Carbone, Alessia +2 more
openaire +2 more sources
Dolutegravir for the treatment of HIV-2 infection
Journal of Clinical Virology, 2015Therapeutic options are limited for HIV-2 infected persons, largely in part due to the lack of susceptibility to HIV-1 non-nucleoside reverse transcriptase inhibitors and poor susceptibility to some HIV-1 protease inhibitors. This is particularly worrisome for HIV-2 patients with prior antiretroviral failure.Report the virological response to ...
Ana Belén Lozano +8 more
openaire +3 more sources